1. Home
  2. NVCR vs TLRY Comparison

NVCR vs TLRY Comparison

Compare NVCR & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TLRY
  • Stock Information
  • Founded
  • NVCR 2000
  • TLRY N/A
  • Country
  • NVCR Switzerland
  • TLRY Canada
  • Employees
  • NVCR N/A
  • TLRY N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TLRY Medicinal Chemicals and Botanical Products
  • Sector
  • NVCR Health Care
  • TLRY Health Care
  • Exchange
  • NVCR Nasdaq
  • TLRY Nasdaq
  • Market Cap
  • NVCR 1.4B
  • TLRY 1.7B
  • IPO Year
  • NVCR 2015
  • TLRY 2018
  • Fundamental
  • Price
  • NVCR $13.77
  • TLRY $1.49
  • Analyst Decision
  • NVCR Buy
  • TLRY Buy
  • Analyst Count
  • NVCR 7
  • TLRY 3
  • Target Price
  • NVCR $28.79
  • TLRY $1.50
  • AVG Volume (30 Days)
  • NVCR 1.6M
  • TLRY 115.8M
  • Earning Date
  • NVCR 10-30-2025
  • TLRY 10-09-2025
  • Dividend Yield
  • NVCR N/A
  • TLRY N/A
  • EPS Growth
  • NVCR N/A
  • TLRY N/A
  • EPS
  • NVCR N/A
  • TLRY N/A
  • Revenue
  • NVCR $630,160,000.00
  • TLRY $830,766,000.00
  • Revenue This Year
  • NVCR $6.68
  • TLRY $6.66
  • Revenue Next Year
  • NVCR $7.01
  • TLRY $4.75
  • P/E Ratio
  • NVCR N/A
  • TLRY N/A
  • Revenue Growth
  • NVCR 14.58
  • TLRY 2.31
  • 52 Week Low
  • NVCR $10.87
  • TLRY $0.35
  • 52 Week High
  • NVCR $34.13
  • TLRY $2.32
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 51.39
  • TLRY 49.72
  • Support Level
  • NVCR $13.57
  • TLRY $1.40
  • Resistance Level
  • NVCR $14.58
  • TLRY $1.54
  • Average True Range (ATR)
  • NVCR 0.64
  • TLRY 0.15
  • MACD
  • NVCR -0.05
  • TLRY -0.05
  • Stochastic Oscillator
  • NVCR 49.59
  • TLRY 11.05

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About TLRY Tilray Brands Inc.

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.

Share on Social Networks: